^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Undisclosed MSC-derived Exosomes with KrasG12D siRNA
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
UT MD Anderson Cancer Center
Drug class:
KRAS G12D inhibitor, Small interfering RNA inhibitor
Related drugs:
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
04/11/2024
Initiation :
01/27/2021
Primary completion :
04/30/2025
Completion :
04/30/2025
KRAS
|
KRAS mutation • KRAS G12D • KRAS G12
|
Undisclosed MSC-derived Exosomes with KrasG12D siRNA
Share
